Lipka AF - Search Results

1

Lipka AF, Verschuuren JJGM. Lipka AF, et al. Handb Clin Neurol. 2024;200:307-325. doi: 10.1016/B978-0-12-823912-4.00012-8. Handb Clin Neurol. 2024. PMID: 38494285 Review.

2

SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma.

Lipka AF, Verschuuren JJ, Titulaer MJ. Lipka AF, et al. Ann N Y Acad Sci. 2012 Dec;1275:70-7. doi: 10.1111/j.1749-6632.2012.06772.x. Ann N Y Acad Sci. 2012. PMID: 23278580 Review.

3

Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome.

Huijbers MG, Lipka AF, Potman M, Hensbergen PJ, Titulaer MJ, Niks EH, van der Maarel SM, Klooster R, Verschuuren JJ. Huijbers MG, et al. Among authors: lipka af. Hum Immunol. 2013 Jul;74(7):849-51. doi: 10.1016/j.humimm.2013.03.004. Epub 2013 Apr 10. Hum Immunol. 2013. PMID: 23583364

4

Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.

Lipka AF, Boldingh MI, van Zwet EW, Schreurs MWJ, Kuks JBM, Tallaksen CM, Titulaer MJ, Verschuuren JJGM. Lipka AF, et al. Neurology. 2020 Feb 4;94(5):e511-e520. doi: 10.1212/WNL.0000000000008747. Epub 2019 Dec 12. Neurology. 2020. PMID: 31831596 Free PMC article.

5

Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome.

Lipka AF, Titulaer MJ, Tannemaat MR, Verschuuren JJGM. Lipka AF, et al. Muscle Nerve. 2020 Jul;62(1):111-114. doi: 10.1002/mus.26885. Epub 2020 Apr 22. Muscle Nerve. 2020. PMID: 32291768 Free PMC article.

6

Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort.

Maddison P, Lipka AF, Gozzard P, Sadalage G, Ambrose PA, Lang B, Verschuuren JJ. Maddison P, et al. Among authors: lipka af. Sci Rep. 2020 Jun 29;10(1):10546. doi: 10.1038/s41598-020-67571-9. Sci Rep. 2020. PMID: 32601396 Free PMC article.

7

Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Ruiter AM, Strijbos E, de Meel RHP, Lipka AF, Raadsheer WF, Tannemaat MR, Verschuuren JJGM. Ruiter AM, et al. Among authors: lipka af. Neuromuscul Disord. 2021 Jul;31(7):622-632. doi: 10.1016/j.nmd.2021.05.006. Epub 2021 May 29. Neuromuscul Disord. 2021. PMID: 34210541 Free article.

8

Prognostic factors for exacerbations and emergency treatments in myasthenia gravis.

de Meel RH, Lipka AF, van Zwet EW, Niks EH, Verschuuren JJ. de Meel RH, et al. Among authors: lipka af. J Neuroimmunol. 2015 May 15;282:123-5. doi: 10.1016/j.jneuroim.2015.03.018. Epub 2015 Mar 26. J Neuroimmunol. 2015. PMID: 25903739

9

Activity limitations in myasthenia gravis and relation to clinical variables.

De Meel RHP, Lipka AF, Van Der Lende M, Van Zwet EW, Tannemaat MR, Verschuuren JJGM. De Meel RHP, et al. Among authors: lipka af. Muscle Nerve. 2017 Jul;56(1):64-70. doi: 10.1002/mus.25463. Epub 2016 Dec 2. Muscle Nerve. 2017. PMID: 27859371

10

Ephedrine treatment for autoimmune myasthenia gravis.

Lipka AF, Vrinten C, van Zwet EW, Schimmel KJ, Cornel MC, Kuijpers MR, Hekster YA, Weinreich SS, Verschuuren JJ. Lipka AF, et al. Neuromuscul Disord. 2017 Mar;27(3):259-265. doi: 10.1016/j.nmd.2016.11.009. Epub 2016 Nov 18. Neuromuscul Disord. 2017. PMID: 28007405 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters